SOPHiA GENETICS priced a $50 million public offering — equivalent to about 13% of its market capitalization — in a move that strengthens the balance sheet for its push into AI-powered cancer diagnostics. Investors greeted the dilutive raise with a 6.3% bump in the stock, suggesting confidence in the commercial trajectory of the company’s decentralized genomic analytics platform.
The Swiss firm operates SOPHiA DDM, a cloud-based software platform that processes complex genomic and imaging data to generate clinical insights. It already markets a suite of CE-IVD marked assays covering solid tumors, HRD status, myeloid cancers, hereditary risk, and RNA-based fusion detection. A liquid biopsy application developed with Memorial Sloan Kettering — MSK-ACCESS powered with SOPHiA DDM — is also commercially available. Earlier-stage programs in radiomics and multimodal data integration are in development.
Commercial biomarkers and platform traction
Despite a fragmented diagnostics landscape, SOPHiA’s platform model sets it apart by enabling decentralized labs to run and interpret complex tests without sending samples to a central hub. The SOPHiA DDM Dx HRD Solution, a homologous recombination deficiency test, captures a growing market as PARP inhibitor use expands. Adoption in Europe has been steady, and longer-term the company eyes the U.S. market through partnerships.
The $50 million raise, priced at an undisclosed discount, provides runway as the company invests in its commercial infrastructure and nascent radiomics and multimodal offerings. While the offering will dilute existing shareholders, the cash infusion could accelerate the path to profitability if the installed base of DDM users and test volume continue to climb.
At $377 million market cap and with a share price of $5.24, SOPHiA trades at a modest multiple relative to other AI-enabled diagnostics peers. The offering follows a pattern of biotechs raising capital opportunistically as the sector shows signs of renewed investor appetite. For SOPHiA, the immediate challenge is converting commercial CE-mark success into sustainable double-digit revenue growth — a metric that will define whether the stock’s post-offering bounce sticks.
